– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeñaGlobe NewsWire News Distribution Service
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024
- Details
- Written by Globe NewsWire Press Releases
- Category: Globe NewsWire News Distribution Service
– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Listen to this article. Speaker link opens in a new window.
Related Bing News Search Results
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024 - Newscast
Theriva Biologics Announces Closing of $7.5 Million Public Offering
Thu, 08 May 2025 13:35:00 GMT Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet ...Maxim Group Downgrades Theriva Biologics (TOVX)
Thu, 08 May 2025 07:24:59 GMT Fintel reports that on May 8, 2025, Maxim Group downgraded their outlook for Theriva Biologics (NYSEAM:TOVX) from Buy to Hold. Analyst Price Forecast Suggests 655.56% Upside As of May 7, 2025, the ...Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong
Wed, 07 May 2025 19:02:49 GMT Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit. The offering is expected to ...Theriva Biologics Announces Pricing of $7.5 Million Public Offering
Wed, 07 May 2025 06:26:00 GMT This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...Theriva Biologics (NYSEAMERICAN:TOVX) Trading 6.8% Higher – Here’s What Happened
Tue, 22 Apr 2025 17:00:00 GMT Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related ...
Related Product Search/Búsqueda de productos relacionados
